ATRX and central nervous system cancer: Grade WHO II/III IDH-mutant gliomas, including oligodendrogliomas (IDH-O) with 1p/19q codeletion and astrocytomas (IDH-A) with intact 1p/19q, show differences in chromatin accessibility and gene expression that correlate with the extent of ATRX loss.